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BACKGROUND The potential for drugs of abuse to induce acute psychotic symptoms is well 
recognised. However, the likelihood of transition from initial substance-induced psychotic disorder 
(SIPD) to chronic psychosis is much less well understood. This study investigated the rate of SIPD 
transition to schizophrenia (F20), the time to conversion, and other possible related factors.  
 
METHODS Using data from the Scottish Morbidity Record, we examined all patients (n=3486) since 
their first admission to psychiatric hospital with a diagnosis of SIPD (ICD-10 codes F10-F19, with third 
digit five) from January 1997 to July 2012. Patients were followed until first episode of schizophrenia 
(ICD-10 code F20, with any third digit) or July 2012. Any change in diagnosis was noted in the follow-up 
period, which ranged from one day to 15.5 years across the groups.  
  
RESULTS  The 15.5 year cumulative hazard rate was 17.3% (SE=0.007) for a diagnosis of 
schizophrenia. Cannabis, stimulant, opiate and multiple drug induced psychotic disorder were all 
associated with similar hazard rates.  The mean time to transition to a diagnosis of schizophrenia was 
around 13 years, although over 50% did so within two years and over 80% of cases presented within five 
years of SIPD diagnosis. Risk factors included male gender, younger age, and longer first admission.   
 
CONCLUSIONS  SIPD episodes requiring hospital admission for more than two weeks are more likely 
to be associated with later diagnosis of schizophrenia. Follow-up periods of more than two years are 
needed to detect the majority of those individuals who will ultimately develop schizophrenia. 
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INTRODUCTION  
The potential for drugs of abuse to induce psychosis is well known, with extensive evidence that 
acute psychotic symptoms can be induced by alcohol, amphetamines, LSD, phencyclidine and 
ketamine, as well as by synthetic novel psychoactive substances (Glass 1989; Paparelli et al 
2011; Zawilska & Wojcieszak 2013). There is also evidence that regular use of psychoactive 
substances is associated with the development of schizophrenia in vulnerable individuals, with 
the strongest evidence for an association with cannabis use (Semple et al 2005; Callaghan et al 
2012 ).  
 
For many users, substance-induced psychotic symptoms resolve completely with abstinence, and 
this is defined in ICD-10 as a psychotic disorder due to a specified psychoactive substance or 
substance-induced psychotic disorder (SIPD) (World Health Organization, 1992). However, 
recent studies suggest that some patients who experience SIPD subsequently develop 
schizophrenia at a higher rate than would be expected. The strongest evidence is for transition to 
chronic psychosis following cannabis-, amphetamine- or alcohol-induced psychosis (Thirthalli & 
Benegal 2006), with estimates of between 25% and 50% converting (Arendt et al 2005; Caton et 
al 2007; Crebbin et al 2009; Kittirattanapaiboon et al 2010). It has also been reported that a 
previous history of stimulant or cannabis-related disorders is associated with increased likelihood 
of later diagnosis of schizophrenia following first admission with a brief psychotic episode (Sara 
et al 2014a; 2014b). Despite this, there have been few studies to date examining long term 
clinical outcomes at a population level following acute SIPD and comparing a range of drugs of 
abuse. One large register-based study from Finland (Niemi-Pynttari et al 2013) found the 
cumulative risk of conversion from SIPD to schizophrenia spectrum disorders to be 46%, 30%, 
and 5% for cannabis-, amphetamine, and alcohol-induced psychoses respectively, with the 
majority converting within three years. 
 
An important question is whether patients who experience SIPD may constitute a clinically high 
risk group for schizophrenia (Fusar-Poli et al 2012). Evidence of a link would enable clinicians 
and patients to understand the risk of developing schizophrenia following an episode of SIPD, 
and to have an understanding of the length of follow up required to pick up as many as possible 
of those who go on to develop schizophrenia. 
 
The current study sought to address these questions by analysing readmission patterns of all 
patients who had a first admission to a Scottish psychiatric hospital with a diagnosis of SIPD 
from 1st January 1997 to 31st July 2012. We aimed to establish the transition rate and mean time 
to transition to a diagnosis of schizophrenia from hospital admission with a new diagnosis of 
SIPD. We also aimed to establish whether any demographic (age at first presentation; gender) or 
clinical (substance attributed to psychotic episode; length of first admission) variables were 
significantly associated with a subsequent diagnosis of schizophrenia. 
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METHODS 
Sample characteristics and inclusion criteria 
The Information Services Division (ISD), a division of National Services Scotland, collects 
mental health activity data nationally from information routinely drawn from hospital 
administrative systems across NHS Scotland. The principal data source is the Scottish Morbidity 
Record Four (SMR04) return (http://isdscotland.org/Health-Topics/Mental-Health/Psychiatric-
Hospital-Activity/), which contains information on all admissions to and discharges from NHS 
mental health hospitals and psychiatric in-patient units within general hospitals in Scotland. 
Diagnosis is coded by International Classification of Diseases, Tenth Revision (ICD-10) codes 
(World Health Organization 1992), which were first introduced in the SMR04 dataset in 1997. 
Anonymization of the national databases and adherence to a Statistical Disclosure Control 
Protocol (http://isdscotland.org/About-ISD/Confidentiality/Disclosure-Protocol-Version-2-
3_webversion.pdf) based on the guidance released by the UK Office of National Statistics ensure 
protection of any personally identifiable information.  
 
In order to obtain an incidence cohort, we initially selected all “first admission” cases, that is, 
patients who had not previously received psychiatric inpatient care, hospitalised between 1st 
January 1997 and 31st July 2012.  We selected all cases with a main diagnosis of SIPD on 
discharge recorded by ICD-10 codes F10.5, F11.5, F12.5, F13.5, F14.5, F15.5, F16.5, F17.5, 
F18.5, and F19.5. Age was defined as age at admission. We then retrieved all of each patient’s 
subsequent admissions to hospitals in Scotland over the follow-up period, which was until a 
patient’s first episode of schizophrenia, or July 2012, whichever came first. 
 
Statistical analysis of sample characteristics 
Independent t-tests, equal variances not assumed, were performed to compare age at first 
admission and length of first admission in males and females. Pearson Chi-square was used to 
compare gender distribution between those who went on to a diagnosis of schizophrenia (F20) 
with those who did not.  
 
Transition rate and mean time to change to schizophrenia 
The proportion of patients with a change in diagnosis to schizophrenia was calculated. Kaplan-
Meier survival analysis with censoring was performed to examine the survival time of the entire 
dataset from first recorded diagnosis of SIP to specific diagnosis of schizophrenia (F20). 
Separate groups of subjects defined by specific substance, gender, length of first admission (>14 
days) and age at first admission (≥30 years) were compared using plots of cumulative survival by 
period of observation. Tests of homogeneity of survival across these strata were conducted using 
the log-rank test and, where significant, were entered into a Cox proportional hazards analysis. 
Plots of cumulative survival, one minus cumulative survival, log survival, log minus log 
survival, and cumulative hazard were obtained for illustration and to check model assumptions. 
Interactions were also explored to examine any interdependence between the significant 
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variables identified. For those patients who did convert to schizophrenia diagnosis, mean time to 
change was calculated. 
 
We repeated these analyses for the broader outcome categories of schizophrenia spectrum 
disorders (see supplementary material). All data analysis was performed using the Statistical 
Package for Social Sciences (SPSS Statistics release 17.0.0). 
 
RESULTS 
There were 3486 cases of first episode SIPD identified in the Scottish hospital admission data 
between 1st January 1997 to 31st July 2012. 
 
Whole sample characteristics 
Table 1 shows the gender distribution of new diagnoses of SIPD by substance subcategory, mean 
and standard deviation (SD) of age at first admission and cumulative hazard (%) of diagnosis 
schizophrenia (F20). The overall male/female ratio was 3.1:1, with an average age of 33.7 years 
(SD=12.9), and an average length of stay in hospital of 31.1 days (SD=444.0). 517 patients 
(14.8%) were subsequently admitted to hospital with a diagnosis of schizophrenia (F20). This 
group had a significantly higher male/female ratio of 5.5:1, compared to those who were not later 
admitted with such a diagnosis (N=2969; male/female ratio 2.8:1 );2(1, N = 3486) =26.43, p 
<0.0001. They also had a statistically significant younger age of first presentation: 28.3 years 
(SD=10.1) vs. 34.6 years (SD=13.1); t(852)=12.63, p<0.0001. Mean admission was also longer 
for those later diagnosed with schizophrenia: 40.5 days (SD=188.4) vs. 27.5 days (SD=142.2), 
but this was not statistically significant; t(1886) = -0.91, p=0.361.  
 
Whole sample transition rate and mean time to change to schizophrenia 
Kaplan-Meier survival analysis with censoring over the 15.5-year period revealed the mean 
survival time from first recorded diagnosis of SIPD to specific diagnosis of schizophrenia to be 
13.4 years (95%CI: 13.2-13.5). The cumulative hazard rate was 17.3% (SE=0.007). Examination 
of covariates found that male gender, length of first admission (>14 days) and age at first 
admission (< 30 years) were significant risk factors, with hazard ratios of 1.6 (95%CI: 1.3-2.0), 
p< 0.0001, for male sex, 2·0 (95%CI 1.7-2.4), p<0.0001, for longer first admission, and 4.8 
(95%CI: 3.9-5.8), p< 0.0001, for younger age at first admission. None of the specific substances 
were significant risk factors to the development of schizophrenia in this regression analysis. 
 
Looking at those who later went on to a diagnosis of schizophrenia as a group, the mean time to 
change in diagnosis was 2.5 years (SD 2.6) and the median time to change in diagnosis was 1.7 
years (range 0-13.5 years). 38.5% had converted within one year of first presentation SIP and the 
conversion rates at two, three, four and five years were 55.3%, 69.1%, 77.4%, and 82.8% 
respectively. 
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Demographic and clinical variables associated with specific substances and subsequent 
diagnostic change to schizophrenia 
As summarised in Table 1, and illustrated by Figure 1, which shows time to change from SIPD 
to a diagnosis of schizophrenia, the 15.5 year cumulative hazard rate to diagnosis was 21.4% (SE 
2.7) for persons with previous cannabis-induced psychosis. For stimulant-induced psychosis the 
rate was 19.1% (SE 2.7) and for those with opioid-induced psychosis the rate was 18.4% (SE 
2.3). The hazard rate was 10.6% (SE 1.0) for persons originally diagnosed as having alcohol-
induced psychosis (n=1038) and 21.5% (SE 1.3) for those with multiple/other substance-induced 
psychosis (n=1369). Sedative-, cocaine-, hallucinogen-, tobacco-, and solvent-induced psychosis 
groups were too small to allow meaningful interpretation and are therefore not shown in Figure 
1. However, it is worth noting a high conversion rate in the cocaine group (23.8%, SE 9.5) and a 
low conversion rate in the hallucinogen group (12%, SE 5.7).  
 
Between-group comparisons of the five largest groups (alcohol-, opioid-, cannabis-, stimulant-, 
and multiple/other drug induced-SIPD) who subsequently received a diagnosis of schizophrenia 
are shown by Tables 2 and 3. Table 2, illustrating between-group demographics, shows broad 
similarities across the groups in terms of gender distribution and mean length of stay. Those who 
developed schizophrenia following an alcohol-induced psychosis were significantly older at first 
SIPD episode when compared to the other groups, with a mean time to diagnosis of between 11.5 
and 13.5 years (Kaplan Meier survival analysis, with censoring). Those diagnosed with 
schizophrenia after a cannabis-induced psychosis were significantly younger, with a mean time 
to diagnosis of between 2.2 and 2.8 years. Table 3 shows between-group comparisons of 
outcomes. The risk of developing schizophrenia was significantly greater for all of the other 
groups when compared to the alcohol-induced psychosis group, where the risk was lowest. 
Between group comparisons for the risk of opioid, cannabis, stimulant and multiple/other drug-
induced episodes of psychosis leading to schizophrenia showed no significant differences. 
 
DISCUSSION 
In the present study, conversion to schizophrenia was estimated at 17.3% of those presenting 
with SIPD. Systematic reviews of studies in which clinical ultra-high risk groups are examined 
found the risk of conversion to be higher, at between 30-40% over two to three year follow-up 
(Gee & Cannon 2011; Fusar-Poli et al 2012). These studies generally focus on young people, 
those with sub-syndromal symptoms or high genetic risk, and with broader definitions of 
schizophrenia spectrum disorder outcomes, whereas our population included older patients 
experiencing psychotic symptoms in the context of both alcohol and drug misuse. 
 
A number of possible mechanisms may underlie this association. Certain psychoactive 
substances may alter brain function, perhaps by altering dopamine receptor sensitivity (Paparelli 
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et al 2011), leading to psychotic illness. It may be that those who experience an acute episode of 
psychosis when using certain substances are already inherently vulnerable to the development of 
chronic psychotic illnesses (Caton et al 2007; Paparelli et al 2011; Bramness et al 2012). Indeed, 
there is evidence for common genetic mutations in those who experience psychotic symptoms in 
response to amphetamines and those with schizophrenia (Ikeda et al 2013), and there is evidence 
that individuals with a diagnosis of schizophrenia are more likely to become acutely psychotic 
with amphetamines than those without (Lieberman et al 1984). Alternatively, the ability of 
substances to induce acute psychotic symptoms in patients who subsequently develop a chronic 
psychosis may reflect a prodromal syndrome (Bramness et al 2012), or that psychoactive 
substances are being used to self-medicate symptoms of an emerging chronic psychosis 
(Chambers et al 2001). 
 
Considering the risk of transition associated with specific substances, the cumulative hazard for 
conversion from diagnosis of cannabis-induced psychosis to schizophrenia in this study was 
21.4%. Other studies have found higher rates – 46% in the Finnish study (Niemi-Pynttari et al 
2013) and 44·5% in the Danish study (Arendt et al 2005) – possibly, in part, because they used 
the broader outcome of schizophrenia spectrum disorder (see Other Supplementary Material). It 
has been proposed that these higher rates suggest that cannabis-induced psychosis tends to occur 
more frequently in patients with a predisposition to developing schizophrenia 
(Kittirattanapaiboon et al 2010). Cannabis may be an independent risk factor both for the 
development of psychotic symptoms and psychotic disorder in vulnerable groups including 
individuals who use cannabis during adolescence, those who have previously experienced 
psychotic symptoms, and those at high genetic risk of developing schizophrenia (Semple et al 
2005). We found that cannabis-induced psychotic disorder was not a specific risk factor to the 
development of schizophrenia; rather those who experienced an episode that converted to 
schizophrenia were significantly younger than any of the other groups. Earlier age of exposure to 
cannabis is also known to increase the chances of later development of schizophrenia (Rubino et 
al 2012). Higher rates of conversion in those who present with cannabis-induced psychotic 
disorder may relate to exposure to cannabis during a vulnerable period in adolescence and early 
adulthood, when there may be disruption of maturational events within the endocannabinoid 
system. The possibility that the endocannabinoid system may have an aetiological role in the 
development of schizophrenia merits further investigation (Murray et al 2013). 
 
The cumulative hazard rates for development of schizophrenia in opiate-induced (18.4%) and 
stimulant-induced (19.1%) psychotic disorder groups were also lower than in the Finnish cohort 
(Niemi-Pynttari et al 2013), which again may be partly related to the broader definition of 
schizophrenia spectrum disorder used in that study. We likewise found the lowest chance of 
conversion to schizophrenia to be in the alcohol-induced psychotic disorder group, with a 
cumulative hazard of 10.6%. The Finnish study found a lower probability of around 5%, despite 
the broader schizophrenia spectrum disorder diagnosis (Niemi-Pynttari et al 2013), but their 
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sample was of 15787 individuals compared to 1038 in our population, and the patterns of alcohol 
misuse or the diagnostic practice of labeling an episode as alcohol-induced psychotic disorder 
may differ between Finland and Scotland. Nevertheless, both studies found this group of patients 
to be relatively older, and previous studies (Schuckit 1983) have not found psychotic symptoms 
in the context of alcohol misuse to be associated with a family history of schizophrenia, 
suggesting that alcohol-induced psychotic disorder may be aetiologically distinct from 
schizophrenia.  
 
The largest group in our study was the ‘multiple/other substance’ group (n=1369). This group 
was very similar to the cannabis-induced psychotic disorder group in terms of age, gender, length 
of stay, and cumulative hazard to development of schizophrenia (21.5% vs 21.4%). It is likely 
that ‘multiple/other substances’ will include cannabis (Arias et al 2013) and this may explain the 
apparent similarities. It is equally possible that exposure to multiple psychoactive substances 
elevates the risk of developing a psychotic disorder to a similar extent as cannabis. Additionally, 
novel psychoactive substances (NPS) are neither routinely screened for, nor is NPS-induced 
psychotic disorder coded separately, and therefore psychotic episodes caused by NPS (Zawilska  
& Wojcieszak  2013; Helander et al 2014) may fall within the F19.5 category. 
 
The main gender differences were the higher proportion of men in the alcohol-induced psychotic 
disorder group and the higher proportion of women in the stimulant-induced psychotic disorder 
group, compared to other substances. This reflects known patterns of drug and alcohol misuse in 
the general population (European Monitoring Centre for Drugs and Drug Addiction 2005). 
Interestingly these differences did not carry over into the groups who went on to develop 
schizophrenia after alcohol- or stimulant-induced psychosis. Gender ratios for all of these groups 
were not significantly different. Male gender was a risk factor to development of schizophrenia 
and schizophrenia spectrum disorders in the survival analyses and this is a finding that is 
replicated across all studies looking at risk factors to development of schizophrenia (Fusar-Poli 
et al 2012). 
 
Those who developed schizophrenia were younger (28.3 vs. 34.6 yrs) at the time of first episode 
SIPD than those who did not, and being under 30 years old was a significant risk factor in the 
survival analysis, increasing the chances of developing schizophrenia by almost a factor of five. 
This may reflect a detrimental effect of exposure to psychoactive substances during critical 
periods of neuronal maturation.  
 
The alcohol-induced psychotic disorder group was significantly older than the other groups. 
Studies have suggested early age of onset of alcohol dependence and chronic alcohol use are a 
necessary prerequisite to the development of alcohol-induced psychotic disorder (Perala et al 
2010). There is also evidence that the specific functional changes associated with alcohol-
induced psychosis are different from those associated with schizophrenia (Jordaan et al 2012). It 
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would be interesting, therefore, to examine the nature of alcohol-related psychosis as it seems 
likely that it is aetiologically distinct from schizophrenia. As well as tending to present in later 
life, it is less likely to be associated with schizophrenia and interventions aimed at tackling 
symptoms such as alcoholic hallucinosis may involve additional strategies to the use of 
antipsychotics (Jordaan et al 2012). 
 
The ICD-10 (World Health Organization 1992) and DSM-5 (American Psychiatric Association 
2013) diagnostic guidelines, along with other studies (Lambert et al 2005; Tucker 2009), suggest 
that the longer the index admission – a proxy for severity - the greater the likelihood of 
conversion to schizophrenia or related psychoses. No such association was found in the Finnish 
study (Niemi-Pynttari et al 2013) and although we did not find a statistical difference between 
the length of stay in hospital when comparing those who converted to schizophrenia with those 
who did not, we did demonstrate that length of stay greater than 14 days doubled the chances of 
developing schizophrenia in the survival analysis. 
 
The present study had a number of limitations. The ISD database covered only data regarding 
hospital admissions in Scotland. We could not exclude the possibility of any previous 
presentation with SIPD to mental health services outside Scotland, any previous presentation 
with SIPD or any subsequent psychotic relapse which may not have required hospital admission 
or which may have led to hospital admission outside Scotland, and we had no information 
regarding deaths occurring during the follow-up period. While it is not possible to categorically 
state that only first admission cases were included, as the ICD-10 codes used were only 
introduced in 1997, admission status was recorded in the same way prior to this, minimizing the 
possibility that patients with admissions prior to 1997 were included. Diagnostic accuracy is a 
common problem with administrative data since clinical diagnoses cannot be verified or 
validated. It is unlikely that this constitutes a major problem in the current study since the 
uniformity of psychiatric training across Scotland and our large national cohort will have 
minimised the impact on the results of any diagnostic discrepancies. It would have been useful to 
have had additional clinical details relating to the nature of the psychotic symptoms experienced 
but this was beyond the scope of the available data. Such additional clinical data would have 
allowed more detailed examination of any specific relationship between particular clinical 
characteristics of SIP and progression to schizophrenia. Additionally, these data did not include 
information on demographic factors such as employment status, socio-economic class or level of 
education which may have had some impact on long-term prognosis. The nature of the available 
data meant that any confirmation of the associated substances by drug screening was not 
recorded. It is unlikely that a diagnosis of a specific substance related psychotic episode would 
have been made without such confirmation. This may explain the fact that the largest category 
was ‘multiple/other substances’ psychotic disorder which may have been used as the default 
diagnosis for any unconfirmed cases where drugs were clearly implicated. It is also possible that 
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this was the largest category simply because patients were taking several substances and it was 
not possible to determine which of these substances caused the episode of SIPD. 
 
The nature of the study design also precluded analysis of any confounding effect that potential 
therapeutic interventions may have exerted on the observed outcomes. This would include 
pharmacological, psychological, and social interventions. Of note, there has been a decline in 
psychiatric inpatient beds across Scotland over the study period and the potential shortening of 
duration of hospitalization following the introduction of home treatment services in some areas 
may have biased the average length of hospital stays. However, given that SIPD episodes tend to 
be short-lived and typically florid, it is questionable whether such changes in healthcare 
provision would have significantly impacted on the clinical management, particularly of first-
episode cases. Other than this general reduction in numbers of admissions, it is not possible to 
say if there were trends in the types of patients admitted to Scottish hospitals during the study 
period. 
 
Current evidence shows that substance misuse disorders are common in those with first episode 
psychosis (Tucker 2009), have a detrimental impact on outcome (Lambert et al 2005), and a 
significant effect on drop-out rates from follow-up (Crebbin et al 2009). Early interventions for 
psychosis that include addressing the issue of substance misuse may have a positive impact on 
longer-term outcomes (Lambert et al 2005). Our data suggest that these interventions ought to 
span at least two or perhaps five years after first presentation of SIPD to aid identification of half 
or three-quarters of those who will develop schizophrenia. 
 
These data suggest that around 17% of those presenting with an acute SIPD transition to  
schizophrenia within five years. With this in mind, future research should address those clinical 
variables that could predict those at elevated risk of subsequently developing schizophrenia 
following an episode of SIP, and what ought to comprise the essential elements of a effective 
treatment plan to reduce that risk. 
 
In summary, these data suggest that psychotic disorder episodes associated with use of cannabis, 
amphetamine, opioids, or multiple/other substances requiring hospital admission are more likely 
to be associated with later diagnosis of schizophrenia than psychoses caused by alcohol. Lengthy 
follow-up periods of around five years are needed to detect the one in six individuals who will 
ultimately develop schizophrenia or a related psychotic disorder. Risk factors include male 
gender, early age of first presentation with SIPD and admission for SIPD lasting over two weeks.
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Table 1 
Summary of patient demographics and risk of conversion (cumulative hazard) to diagnosis of schizophrenia (F20) across specific 
substance sub-groups  
 
 
 
Table 2 
Between group demographics & length of inpatient stay for selected cohorts who received a subsequent diagnosis of schizophrenia 
(F20) 
 
a Significantly older than all other groups: p < 0·0001 
b Significantly younger than all other groups: p < 0·0001 for alcohol, p = 0·005 for opioids, p = 0·018 for stimulants, p = 0·007 for 
multiple/other 
 
 
ICD-10 Code Substance 
Total 
n 
Men 
n (%) 
Women  
n (%) 
Mean age  
in yrs (sd)  
Cumulative hazard (with 
censoring) 
% (SE) 
F10·5 Alcohol 1038 80 (83·5) 237 (16·5) 44·5 (13·1) 10·6 (1·0) 
F11·5 Opioids 419 309 (73·7) 110 (26·3) 30·1 (10·1) 18·4 (2·3) 
F12·5 Cannabis 276 214 (77·5) 62 (22·5) 28·2 (9·1) 21·4 (2·7) 
F13·5 Sedatives 35 20 (57·1) 15 (42·9) 33·8 (13·3) 14·5 (6·9) 
F14·5 Cocaine 24 20 (83·3) 4 (16·7) 28·9 (7·4) 23·8 (9·5) 
F15·5 Stimulants 273 183 (67·0) 90 (33·0) 30·4 (10·6) 19·1 (2·7) 
F16·5 Hallucinogens 36 26 (72·2) 10 (27·8) 23·2 (6·5) 12 (5·7) 
F17·5 Tobacco 2 1 (50) 1 (50) 46·5 (20·5) N/A 
F18·5 Solvents 14 12 (85·7) 2 (14·3) 27·1 (9·5) 22·1 (14·1) 
F19·5 Multiple/Other 1369 1048 (76·6) 321 (23·4) 28·8 (9·4) 21·5 (1·3) 
All Any 3486 2634 (75·6) 852 (24·4) 33·9 (12·9) 17·3 (0·007) 
ICD-10 Code Substance 
Total 
N 
Men 
n (%) 
Women 
n (%) 
Mean age  
in yrs (SD) 
Mean length of stay  
in days (SD) 
F10·5 Alcohol 99 82 (82·8) 17 (17·2) 39·2a (12·5) 33·8 (72·3) 
F11·5 Opioids 63 54 (85·7) 9 (14·3) 26·7 (7·2) 38·6 (76·7) 
F12·5 Cannabis 52 46 (88·5) 6 (11·5) 23·1b (6·5) 33·4 (35·4) 
F15·5 Stimulants 46 39 (84·8) 7 (15·2) 26·5 (7·4) 34·4 (45·6) 
F19·5 Multiple/Other 242 204 (84·3) 38 (15·7) 25·9 (7·6) 31·2 (76·6) 
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Table 3 
Between group comparisons of outcome measures for selected cohorts who received a subsequent diagnosis of schizophrenia 
(F20) 
 
a A hazard ratio of one indicates the comparator group 
 
ICD-10 Code Substance 
Kaplan-Meier mean 
survival time to F20  
in years (SE) 
Mean time to change 
to F20  
in years (SD) 
Hazard ratio for conversion to F20  
(95% CI); p value 
F10·5 Alcohol 13·5 (0·2) 2·6 (2·7) 1a 
F11·5 Opioids 12·8 (0·3) 2·8 (2·9) 1.679 (1.224 – 2.303); p=0.00130 
F12·5 Cannabis 11·5 (0·4) 2·2 (2·1) 2.253 (1.610 – 3.152); p<0.0001 
F15·5 Stimulants 12·0 (0·4) 2·3 (2·7) 1.891 (1.333 – 2.683); p=0.00035 
F19·5 Multiple/Other 11·8 (0·2) 2·5 (2·6) 2.086 (1.651 – 2.636); p<0.0001 
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Figure 1  
Hazard function with censoring illustrating time to change from SIP to schizophrenia in a cohort of patients first-ever admitted to any 
Scottish psychiatric hospital between January 1997 and July 2012 subdivided by substance attributed to psychotic episode 
 
